Mangalam Drugs & Organics Limited (MDOL) has announced a significant development in its international business operations. The company has secured a repeat export order for Anti-Malarial Active Pharmaceutical Ingredient (API) from a reputed international client. This order marks a notable achievement for the company in the global pharmaceutical market.

Order Details

Impact on Company's Position

The receipt of this order is expected to have several positive implications for Mangalam Drugs & Organics Limited:

1. Market Position: This repeat order strengthens the company's position in the global pharmaceutical market, particularly in the anti-malarial segment.

2. Growth Trajectory: The company anticipates that this order may contribute positively to its growth trajectory in the coming quarters.

3. Revenue Visibility: The order is expected to enhance revenue visibility for MDOL in the near term.

Execution and Compliance

Mangalam Drugs & Organics Limited has confirmed that the order will be executed over the next 2-4 months. The company has made this disclosure in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Company's Commitment

In light of this development, MDOL has reiterated its commitment to delivering high-quality pharmaceutical products to both domestic and international clients. This approach aligns with the company's goal of enhancing shareholder value through consistent performance in the global market.

The successful securing of this repeat order suggests a strong relationship with international clients and potentially indicates the quality and reliability of MDOL's Anti-Malarial API products. As the global fight against malaria continues, such orders highlight the important role played by Indian pharmaceutical companies in the international healthcare supply chain.

Investors and market watchers will likely keep a close eye on how this order impacts Mangalam Drugs & Organics Limited's financial performance in the upcoming quarters.

Mangalam Drugs & Organics Limited, a pharmaceutical company, has reported a default on its loan obligations to two major banks, totaling Rs 765.19 lacs. The company attributes this financial stress to reduced funding and decreased orders for specific treatments.

Loan Default Details

The defaults, which have exceeded 30 days, began in October 2025 for both banks. Mangalam Drugs & Organics has formally disclosed this information to comply with stock exchange regulations.

Reasons for Financial Stress

The company cites two primary factors contributing to its current financial difficulties:

1. Discontinuation of US Aid Funding: The US government has disbanded funding from US Aid, which was a significant source of support for Mangalam's business operations.

2. Reduced Treatment Orders: There has been a drop in orders for treatments related to TB, HIV, and Malaria. Currently, only the Global Fund is providing funding, but with a reduced budget.

Company's Response

Mangalam Drugs & Organics has taken the following steps to address the situation:

• Requested a loan restructuring with their banks
• Plans to submit a desired restructuring plan by mid-December 2025
• Making arrangements to pay the overdue amount

The company's Chief Financial Officer, Ajay Samant, has stated that they will keep stakeholders updated on the progress of discussions with the banks and the resolution of the default.

This development highlights the challenges faced by pharmaceutical companies that rely on international aid and funding for specific disease treatments. The situation underscores the importance of diversified funding sources and adaptable business models in the pharmaceutical industry.